Valsartan ingestions among adults reported to Texas poison control centers, 2000 to 2005
- Mathias B. Forrester
- … show all 1 hide
Little data exist on potentially adverse valsartan ingestions reported to poison control centers.
Using adult ingestions of valsartan reported to Texas poison control centers during 2000–2005, I determined the proportion of cases involving serious outcomes for selected variables and evaluated for statistical significance by calculating the rate ratio (RR) and 95% confidence interval (CI).
Thirteen (7%) of 185 total cases involved serious outcomes. Serious outcomes were significantly more likely to occur with a maximum dose > 320 mg (RR 9.06, CI 1.30–100.14) or >4 tablets (RR 9.00, CI 2.07–39.11) or where the circumstances of the exposures involved self-harm or malicious intent (RR 17.28, CI 4.98–67.13).
The severity of the medical outcome associated with adult valsartan ingestions depended on the dose and the circumstances of the ingestion. Such information is useful for creating triage guidelines for the management of adult valsartan ingestions.
- Dina, R, Jafari, M (2000) Angiotensin II-receptor antagonists: an overview. Am J Health Syst Pharm. 57: pp. 1231-1241
- Israili, ZH (2000) Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens. 14: pp. S73-S86 CrossRef
- McInnes, GT (1999) Clinical advantage of valsartan. Cardiology 91: pp. 14-18 CrossRef
- Leiken, JB, Paloucek, FP eds. (1998) Poison and Toxicology Compendium with Symptoms Index. Lexi-Corp Inc, Hudson, Ohio
- Novartis. Diovan® valsartan tablets. [updated 2006 Apr;cited2006 Oct 31]. Available from: http://www.pharma.us.novartis.com/product/pi/pdf/diovan.pdf
- Pfeffer, MA, McMurray, JJ, Velazquez, EJ, Rouleau, JL, Kober, L, Maggioni, AP, Solomon, SD, Swedberg, K, Werf, F, White, H, Leimberger, JD, Henis, M, Edwards, S, Zelenkofske, S, Sellers, MA, Califf, RM (2003) Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 349: pp. 1893-1906 CrossRef
- Cohn, JN, Tognoni, G (2001) Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 345: pp. 1667-1675 CrossRef
- Watson, WA, Litovitz, TL, Klein-Schwartz, W, Rodgers, GC, Youniss, J, Reid, N, Rouse, WG, Rembert, RS, Borys, D (2003) annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 22: pp. 335-404 CrossRef
- Watson, WA, Litovitz, TL, Rodgers, GC, Klein-Schwartz, W, Reid, N, Youniss, J, Flanagan, A, Wruk, KM (2004) Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 23: pp. 589-666 CrossRef
- Olson, KR, Erdman, AR, Woolf, AD, Scharman, EJ, Christianson, G, Caravati, EM, Wax, PM, Booze, LL, Manoguerra, AS, Keyes, DC, Chyka, PA, Troutman, WG (2005) Calcium channel blocker ingestion: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 43: pp. 797-822
- Wax, PM, Erdman, AR, Chyka, PA, Keyes, DC, Caravati, EM, Booze, L, Christianson, G, Woolf, A, Olson, KR, Manoguerra, AS, Scharman, EJ, Troutman, WG (2005) Beta-blocker ingestion: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 43: pp. 131-146
- Valsartan ingestions among adults reported to Texas poison control centers, 2000 to 2005
Journal of Medical Toxicology
Volume 3, Issue 4 , pp 157-163
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- poison centers
- adverse exposures
- Industry Sectors
- Author Affiliations
- 1. Texas Department of State Health Services, Austin, Texas